Proving the Business Case for the Internet of Things

Start-up comes out of stealth to launch glucose monitor

Steve Rogerson
May 22, 2018



California start-up LifePlus has entered the multi-billion-dollar smart medical wearables category with the introduction of Lifeleaf, a non-invasive continuous blood glucose monitoring multi-sensor wearable.
 
In addition to blood glucose monitoring, the patent-pending device monitors heart rate, blood pressure, respiration rate and oxygen saturation. It is said to be the first of its kind to monitor non-invasively the top five physiological health indicators and is based on an open standards based software stack that is also available to license. LifeLeaf is active in five trials around the world.
 
The company is backed by Silicon Valley-based JLA Advisors with industry visionary, serial tech-entrepreneur and White House Innovation Fellow John Trobough serving as executive chairman.
 
“We have been in stealth mode and today we are thrilled to announce the introduction of LifeLeaf as part of the burgeoning medical wearables category,” said Trobough. “Managing diabetes and other chronic diseases requires early and timely detection, rapid intervention and high compliance. LifeLeaf exceeds those requirements with its patent-pending open standards-based software stack and cloud-based analytics. LifeLeaf is different from any other product and software technology available; it is truly unique and we are excited to make this multi-sensor capability available to companies and developers globally.”
 
The wearable smartwatch continuously and non-invasively monitors and tracks major chronic health risks such as diabetes, cardiac arrhythmia, congestive heart failure, COPD, sleep apnoea and hypertension. It is a cloud-based AI product with a user interface that is simple and easy to use, as well as a connected mobile app that provides cloud-based analytics with real-time notifications. The product is targeted at the multi-billion-dollar medical wearables market, with an emphasis on the self-monitoring blood glucose market. It will be available later this year.